The companies signed an agreement earlier this year to jointly develop microbiome research services for international markets including a shotgun metagenomic sequencing-based service.
The funds will support Curetis' R&D efforts, which include partnering its Unyvero A30 RQ mid-plex diagnostics system for verification and validation testing.
The company said it will use the funding in part to accelerate the development of products based on its proprietary de novo nucleic acid synthesis technology.
The BGI Group subsidiary said it plans to strengthen its R&D and instrument production, targeting a global sequencing market it expects to grow to $12.45 billion in 2022.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
